Among these inhibitors, pyruvate dehydrogenase kinase (PDK) inhibitors have been suggested to suppress tumor metabolism and inhibit tumor growth in KRAS-mutant PDAC, thereby making them one of the promising areas of continued future research [71]. This evidence concerns the gene KRAS and neoplasm.